EMA/144878/2021

European Medicines Agency decision

P/0096/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for interferon beta-1a (EMEA-002238-PIP01-17-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0096/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for interferon beta-1a (EMEA-002238-PIP01-17-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0305/2018 issued on 12 September 2018,

Having regard to the application submitted by Faron Pharmaceuticals Ltd on 28 September 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for interferon beta-1a, powder for solution for injection, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Faron Pharmaceuticals Ltd., Joukahaisenkatu 6, 20520 - Turku, Finland.

EMA/PDCO/579759/2020
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-002238-PIP01-17-M01

Scope of the application

Active substance(s):

Interferon beta-1a

Condition(s):

Treatment of acute respiratory distress syndrome (ARDS)

Pharmaceutical form(s):

Powder for solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Faron Pharmaceuticals Ltd

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Faron Pharmaceuticals Ltd submitted to the European Medicines Agency on 28 September 2020 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0305/2018 issued on 12 September 2018.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 1 December 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of acute respiratory distress syndrome (ARDS)

2.1.1. Indication(s) targeted by the PIP

Treatment of moderate to severe paediatric ARDS (PARDS)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1:** Development of a paediatric presentation of the powder for solution for injection
Non-clinical studies	0	Not applicable
Clinical studies	2	**Study 2:** Open-label, single arm, multiple dose, uncontrolled trial to evaluate pharmacokinetics (PK), pharmacodynamics (PD) and safety of interferon beta-1a in children from birth to less than 18 years of age with moderate or severe paediatric acute respiratory distress syndrome (PARDS). **Study 3:** Double-blind, randomised, placebo-controlled trial to evaluate safety and efficacy of interferon beta-1a in children from birth to less than 18 years of age with severe PARDS.
Extrapolation, modelling and simulation studies	1	**Study 4:** Extrapolation study to evaluate the use of interferon beta-1a in the treatment of moderate PARDS in children from birth to less than 18 years of age.

Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes